Verteporfin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Verteporfin
- Verteporfin: From Macular Degeneration to Mitochondrial Oxidative Phosphorylation Disorder Due to Nuclear DNA Anomalies
Verteporfin: From Macular Degeneration to Mitochondrial Oxidative Phosphorylation Disorder Due to Nuclear DNA Anomalies
One-Sentence Summary
Verteporfin is a photosensitizer used in photodynamic therapy, originally for macular degeneration. The TxGNN model predicts it may be effective for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Macular degeneration (the Singapore licence has no indication text on file) |
| Predicted New Indication | Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data compiled for this report. Verteporfin is known as a light-activated photosensitizer that occludes abnormal blood vessels in neovascular macular degeneration. It is also known experimentally as an inhibitor of the YAP-TEAD interaction.
Neither mechanism is clearly linked to oxidative phosphorylation defects caused by nuclear DNA anomalies. These are inherited disorders of cellular energy production, and no plausible connection is evident from the available data. The prediction is therefore best treated as a hypothesis-generating signal from the model, not as a mechanistically supported finding.
Other predicted indications were also reviewed. All are at L4–L5 and remain on Hold:
| Rank | Predicted Indication | Score | Evidence Level | Note |
|---|---|---|---|---|
| 2 | Esophageal varices with bleeding | 98.86% | L5 | Prediction only. Photodynamic vascular occlusion could raise bleeding risk in portal hypertension. |
| 3 | Esophageal varices without bleeding | 98.86% | L5 | Same score as rank 2, likely a near-duplicate node. |
| 4 | Exocrine pancreatic insufficiency | 98.57% | L4 | One preclinical paper on YAP and pancreatic fibrosis (indirect). |
| 5 | Varicose disease | 97.06% | L5 | Prediction only. |
| 6 | MRCS syndrome | 96.16% | L5 | Prediction only. |
| 7 | Pigmented paravenous retinochoroidal atrophy | 96.06% | L5 | Ocular, but not a neovascular condition. |
| 8 | Familial flecked retinopathy | 95.08% | L5 | Loose contextual fit only. |
| 9 | Ectopia lentis-chorioretinal dystrophy-myopia syndrome | 94.83% | L5 | No identifiable mechanism. |
| 10 | Retinal dystrophy in systemic or cerebroretinal lipidoses | 94.56% | L4 | One general review of ocular photodynamic therapy. |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top-ranked indication.
For reference, the lower-ranked predictions have only the following publications:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39818090 | 2025 | Preclinical/Mechanistic | International Immunopharmacology | YAP promotes pancreatic fibrosis via macrophage-to-myofibroblast transdifferentiation in chronic pancreatitis. Relevant to exocrine pancreatic insufficiency only indirectly. |
| 17579286 | 2007 | Review | Ophthalmologica | Review of ocular photodynamic therapy, covering standard uses and new indications. Not specific to retinal dystrophy in lipidoses. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11608P | VISUDYNE FOR INJECTION 15 mg/vial | Injection | Not stated in the available record |
Safety Considerations
- Contraindications (from the knowledge graph, not label text): inherited porphyria, porphyrin metabolism disease, porphyria, liver disease, gallbladder disease.
- Drug Interactions: 100 interactions were found. The sample reviewed was mostly Moderate, with one Minor (polymyxin B). Main examples:
- Tetracycline-class antibiotics: doxycycline, tetracycline, minocycline (including topical forms)
- Sulfonylurea antidiabetics: chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, acetohexamide
- Others: acetylsalicylic acid, levofloxacin, mannitol, sulfasalazine, beta carotene, papaverine
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for mitochondrial oxidative phosphorylation disorder is supported only by a model score. There are no trials or publications, and no plausible mechanistic link. None of the other nine predicted indications has direct clinical evidence either.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Health Sciences Authority (HSA), which are required before any safety screening
- Verteporfin mechanism of action data (for example from DrugBank)
- Mechanistic or preclinical evidence linking verteporfin to nuclear-DNA-related oxidative phosphorylation defects
- Full-text review of PMID 39818090 if exocrine pancreatic insufficiency is pursued as an alternative candidate
- Safety assessment of the KG-listed contraindications (porphyria, liver and gallbladder disease) in any new patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.